Greenbrook TMS Inc. Finalizes Court Approval for Arrangement
Greenbrook TMS Inc. (OTC: GBNHF) is excited to share that it has successfully received a crucial court approval from the Ontario Superior Court of Justice. This final order endorses the plan of arrangement with Neuronetics, Inc., which aims to enhance the services provided by Greenbrook, a leader in mental health treatment.
Details of the Arrangement
The approved arrangement will see Neuronetics acquire all outstanding common shares of Greenbrook. Upon completion, each common share will be traded for a specific fraction of Neuronetics' stock, a move anticipated to bolster the operational capacity and reach of Greenbrook's TMS services.
Shareholders' Support
At a recent special meeting, stakeholders expressed overwhelming support for this decision, with over 99% voting in favor of the arrangement. This robust approval underlines the confidence shareholders have in the strategic direction of the company.
Future Implications
Following this arrangement, Neuronetics plans to delist Greenbrook's shares from the OTCQB Market, signifying a major transition in the company’s operational structure. Additionally, Greenbrook will pursue to discontinue its reporting requirements, allowing a streamlined focus on growth and service delivery.
Greenbrook's Commitment to Mental Health
Greenbrook operates 118 treatment centers across the United States, offering Transcranial Magnetic Stimulation (TMS) and Spravato®, both FDA-cleared treatments for Major Depressive Disorder (MDD) and other mental health conditions. TMS therapy is known for its effectiveness, utilizing electromagnetic fields to stimulate brain regions tied to mood regulation.
Distribution of Treatments
To date, Greenbrook has delivered over 1.61 million treatments to more than 49,000 patients, helping individuals overcome the challenges of depression. The commitment to innovative mental health solutions remains at the forefront of Greenbrook's mission.
Ongoing Developments
As Greenbrook embarks on this new chapter, it is crucial to acknowledge the factors that will influence the successful completion of the arrangement. The final agreement hinges on satisfying customary closing conditions, which are currently being addressed.
Contact Information
For any inquiries, please reach out to Glen Akselrod, the Investor Relations representative at Greenbrook. He is available for questions and further discussions regarding the transition process.
Frequently Asked Questions
What is the significance of the court approval for Greenbrook?
The court approval is a pivotal step in finalizing the arrangement with Neuronetics, enabling Greenbrook to enhance its operational capacity in mental health treatment.
How will the arrangement impact Greenbrook's services?
The arrangement is expected to increase Greenbrook's resources and capabilities, helping to provide more comprehensive mental health solutions to its patients.
Who should I contact for more information about Greenbrook?
Glen Akselrod is the designated contact for all inquiries related to the company's operational changes and future directions.
What treatments does Greenbrook provide?
Greenbrook specializes in Transcranial Magnetic Stimulation (TMS) and Spravato® therapies for the treatment of Major Depressive Disorder and other mental health issues.
What is the next step after this court approval?
Following the court's seal of approval, Greenbrook will move forward to satisfy the necessary closing conditions before officially completing the arrangement.
